Group 1 - Company has entered into a placement agreement with joint placement agents Morgan Stanley and Goldman Sachs to issue 55 million placement shares, representing approximately 3.33% of the total issued shares as of the announcement date [1] - The expected total proceeds from the placement are approximately HKD 4.3098 billion, with net proceeds estimated at around HKD 4.2654 billion [1] - Approximately 90% of the net proceeds will be used to advance the company's clinical and preclinical innovative pipeline globally, while about 10% will be allocated for daily operations [1] Group 2 - The company aims to grow into a world-class biopharmaceutical enterprise, leveraging a strong R&D platform and a rich pipeline to enter a new growth cycle [2] - The global layout of the innovative pipeline is becoming a significant growth engine for the company, showcasing its core competitiveness [2] - The placement is expected to better support the company's globalization efforts and provide more flexibility in pipeline development, ultimately creating sustainable long-term returns for the company and its shareholders [2]
信达生物(01801.HK)拟配售5500万股总筹43亿港元 重点投入临床研发及全球化布局